

TABLE OF CONTENTS

0. Executive Summary	24
1. Introduction to Cell Therapy	28
Introduction.....	28
Historical landmarks of cell therapy.....	28
Interrelationship of cell therapy technologies	30
Cells and organ transplantation	30
Cells and protein/gene therapy	31
Cell therapy and regenerative medicine.....	32
Cells therapy and tissue engineering	32
Therapy based on cells involved in disease	33
Advantages of therapeutic use of cells.....	33
Cell-based drug delivery	34
<i>Cells as vehicles for gene delivery</i>	<i>34</i>
<i>Red blood cells as vehicles for drug delivery</i>	<i>34</i>
<i>Advantages of cell-based drug delivery</i>	<i>35</i>
<i>Limitations of cell-based drug delivery</i>	<i>35</i>
2. Cell Therapy Technologies	36
Introduction.....	36
Cell types used for therapy	36
Sources of cells.....	36
Xenografts	37
Cell lines.....	37
<i>Immortalized cells.....</i>	<i>37</i>
Blood component therapy	37
<i>Therapeutic apheresis.....</i>	<i>37</i>
<i>Leukoreduction</i>	<i>38</i>
<i>Platelet therapy</i>	<i>38</i>
Basic technologies for cell therapy	39
Cell culture.....	39
<i>Automated cell culture devices.....</i>	<i>39</i>
<i>Cell culture for adoptive cell therapy.....</i>	<i>40</i>
<i>Observation of stem cell growth and viability.....</i>	<i>40</i>
<i>Companies involved in cell culture</i>	<i>40</i>
Cell sorting.....	42
<i>Flow cytometry</i>	<i>42</i>
<i>A dielectrophoretic system for cell separation</i>	<i>43</i>
<i>Adult stem cell sorting by identification of surface markers.....</i>	<i>43</i>
<i>ALDESORTER system for isolation of stem cells.....</i>	<i>43</i>
<i>Dynabead technology for cell sorting</i>	<i>43</i>
<i>Molecular beacons for specific detection and isolation of stem cells.....</i>	<i>44</i>
<i>Multitarget magnetic activated cell sorter.....</i>	<i>44</i>
<i>Nanocytometry</i>	<i>44</i>
<i>Scepter™ cytometer.....</i>	<i>45</i>
<i>Companies supplying cell sorters</i>	<i>45</i>
Cell analysis	46
<i>Cell analyzers</i>	<i>46</i>
<i>In vivo cell imaging</i>	<i>46</i>
<i>Measuring cell density</i>	<i>47</i>
Single-cell gene expression analysis.....	47
Preservation of cells	48
<i>Innovations in cryopreservation</i>	<i>48</i>
Packaging of cells.....	49
Selective expansion of T cells for immunotherapy	49
Cloning and cell therapy	50
Techniques for cell manipulation	50
Cell-based drug discovery.....	51
Advantages and limitations of cell-based assays for drug discovery	51
<i>Advantages and limitations of cell-based toxicity screening</i>	<i>51</i>
<i>Quality control of cells for drug discovery.....</i>	<i>52</i>
Companies involved in cell-based drug discovery	52
Drug delivery systems for cell therapy.....	54
Intravenous delivery of stem cells.....	54
Pharmacologically active microcarriers.....	54
Devices for delivery of cell therapy.....	55
Artificial cells	56

Applications of artificial cells.....	56
Cell encapsulation.....	56
Diffusion capsule for cells.....	57
Encapsulated cell biodelivery.....	57
Therapeutic applications of encapsulated cells.....	57
Nitric oxide delivery by encapsulated cells.....	59
Implantation of microencapsulated genetically modified cells.....	59
Ferrofluid microcapsules for tracking with MRI.....	60
Companies involved in encapsulated cell technology.....	60
Electroporation.....	61
Gene therapy.....	61
Cell-mediated gene therapy.....	62
<i>Fibroblasts</i>	62
<i>Chondrocyte</i>	63
<i>Skeletal muscle cells</i>	63
<i>Vascular smooth muscle cells</i>	64
<i>Keratinocytes</i>	64
<i>Hepatocytes</i>	64
<i>Lymphocytes</i>	64
<i>Mammalian artificial chromosomes</i>	65
In vivo tracking of cells.....	65
Molecular imaging for tracking cells.....	65
<i>MRI technologies for tracking cells</i>	66
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	67
<i>Visualization of gene expression in vivo by MRI</i>	67
Role of nanobiotechnology in development of cell therapy.....	67
Cell transplantation for development of organs.....	68
Cells transplantation and tolerance.....	68
Strategies to improve tolerance of transplanted cells.....	69
<i>Encapsulation to prevent immune rejection</i>	69
<i>Prevention of rejection of xenotransplants</i>	69
<i>Expansion of allospecific regulatory T cells</i>	69
Removal and replacement of pathogenic cells of the body.....	70
Therapeutic leukocytapheresis.....	70

3. Stem Cells..... 72

Introduction.....	72
Biology of stem cells.....	73
Embryonic stem cells.....	73
Growth and differentiation of ESCs.....	73
Mechanisms of differentiation of ESCs.....	74
<i>Chemical regulation of stem cell differentiation</i>	74
<i>In vitro differentiation of hESCs</i>	74
<i>SIRT1 regulation during stem cell differentiation</i>	74
Regulation of stem cell self-renewal and differentiation.....	75
<i>hESCs for reprogramming human somatic nuclei</i>	75
<i>Stem cells differentiation in the pituitary gland</i>	75
Influence of microenvironment on ESCs.....	76
Role of genes in differentiation of ESCs.....	76
<i>Global transcription in pluripotent ESCs</i>	76
<i>Role of p53 tumor suppressor gene in stem cell differentiation</i>	77
<i>Role of Pax3 gene in stem cell differentiation</i>	77
<i>Signaling pathways and ESC genes</i>	77
Epigenetics of hESCs.....	78
<i>Chromatin as gene regulator for ESC development</i>	78
Comparison of development of human and mouse ESCs.....	79
Mechanism of regulation of stem cells for regeneration of body tissues.....	79
<i>Role of microenvironments in the regulation of stem cells</i>	80
<i>Regulation and regeneration of intestinal stem cells</i>	80
Parthenogenesis and human stem cells.....	80
<i>Uniparental ESCs</i>	81
Bone marrow stem cells.....	82
<i>Hematopoietic stem cells</i>	82
<i>Role of HSCs in the immune system</i>	84
<i>Derivation of HSCs from ESCs</i>	84
<i>Mesenchymal stem cells</i>	84
<i>Multipotent adult progenitor cells</i>	86
<i>Side population (SP) stem cells</i>	86
Differentiation of adult stem cells.....	87
Growth and differentiation of HSCs.....	88
<i>Signaling pathways in the growth and differentiation of HSCs</i>	88

<i>Mathematical modeling of differentiation of HSCs</i>	88
<i>Role of prions in self renewal of HSCs</i>	89
Sources of stem cells	89
Sources of of human embryonic stem cells	89
Nuclear transfer to obtain hESCs.....	89
Direct derivation of hESCs from embryos without nuclear transfer.....	90
Alternative methods of obtaining hESCs.....	91
<i>Establishing hESC lines without destruction of embryo</i>	91
<i>Altered nuclear transfer</i>	92
<i>Small embryonic-like stem cells</i>	92
Advantages and disadvantages of ESCs for transplantation	93
Use of ESC cultures as an alternative source of tissue for transplantation.....	93
Spermatogonial stem cells	94
Amniotic fluid as a source of stem cells.....	95
<i>Amniotic fluid stem cells for tissue repair and regeneration</i>	95
<i>Generation of iPS cells from AF cells</i>	95
Placenta as source of stem cells.....	96
<i>Amnion-derived multipotent progenitor cells</i>	96
<i>Placenta as a source of HSCs</i>	97
<i>Umbilical cord as a source of MSCs</i>	97
Umbilical cord blood as source of neonatal stem cells	97
<i>Cryopreservation of UCB stem cells</i>	98
<i>UCB as source of MSCs</i>	99
<i>Applications of UCB</i>	99
<i>Advantages of UCB</i>	99
<i>Limitations of the use of UCB</i>	100
<i>Licensing and patent disputes involving UCB</i>	101
<i>Infections following UCB transplants</i>	101
<i>Unanswered questions about UCB transplantation</i>	102
<i>Companies involved in UCB banking</i>	102
<i>UCB banking in the UK</i>	103
<i>US national UCB banking system</i>	104
<i>Future prospects of UCB as a source of stem cells</i>	105
Induced pluripotent stem cells derived from human somatic cells	105
Characteristics of iPSCs	106
DNA methylation patterns of iPS cells	106
iPSCs derived from oocytes through SCNT.....	106
iPSCs derived from skin	107
iPSCs derived from blood	107
Use of retroviral vectors for generation of iPSCs	108
Use of non-integrating viral vectors for generation of iPSCs.....	108
Generation of clinically relevant iPSCs	109
<i>Generation of RBCs from iPSCs</i>	110
<i>iPSCs and disease modeling</i>	110
<i>iPSCs for patient-specific regenerative medicine</i>	111
<i>Concluding remarks about clinical potential of iPSCs</i>	111
Induced conditional self-renewing progenitor cells	111
Sources of adult human stem cells	112
Adipose tissue as a source of stem cells.....	112
<i>Intravenous infusion of adipose tissue derived MSCs</i>	113
<i>iPSCs derived from adult human adipose stem cells</i>	113
<i>Regulation of adipose stem cells differentiation</i>	113
<i>Transforming adult adipose stem cells into other cells</i>	114
Multipotent stem-like cells derived from vascular endothelial cells.....	114
Skin as a source of stem cells.....	114
<i>Controlling the maturation of embryonic skin stem cells</i>	114
<i>Epidermal neural crest stem cells</i>	115
<i>Follicle stem cells</i>	115
<i>Mesenchymal stem cells in skin</i>	116
<i>Regulation of stem cells in hair follicles</i>	116
<i>Skin-derived precursor cells</i>	116
Stem cells in teeth	117
Peripheral blood stem cells.....	117
Spleen as a source of adult stem cells	118
Search for master stem cells	118
Vascular cell platform to self-renew adult HSC.....	118
Adult stem cells vs embryonic stem cells	119
Biological differences between adult and embryonic stem cells	119
Neural crest stem cells from adult hair follicles	119
Transdifferentiation potential of adult stem cells	120
Limitations of adult stem cells	121

Comparison of human stem cells according to derivation	121
VENT cells	122
Stem cell banking	122
Stem cell technologies	123
Analysis of stem cell growth and differentiation	123
Tracking self-renewal and expansion of transplanted muscle stem cells	123
Stem cell biomarkers	123
<i>Endoglin as a functional biomarker of HSCs</i>	124
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	124
<i>SSEA-4 as biomarker of MSCs</i>	124
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	124
<i>Neural stem cell biomarker</i>	125
<i>Protein expression profile as biomarker of stem cells</i>	125
<i>Real-time PCR for quantification of protein biomarkers</i>	125
Study of stem cell pathways	126
Study of stem cell genes	126
Gene inactivation to study hESCs	126
<i>RNAi to study gene inactivation in hESCs</i>	127
<i>Study of ESC development by inducible RNAi</i>	127
<i>Targeting Induced Local Lesions in Genomes</i>	128
<i>Homologous recombination of ESCs</i>	128
<i>Immortalization of hESCs by telomerase</i>	128
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease	129
miRNA and stem cells	129
<i>Role of miRNAs in gene regulation during stem cell differentiation</i>	129
<i>Influence of miRNA on stem cell formation and maintenance</i>	130
<i>Transcriptional regulators of ESCs control miRNA gene expression</i>	130
Stem cells and cloning	131
<i>Cell nuclear replacement and cloning</i>	131
<i>Nuclear transfer and ESCs</i>	131
<i>Cloning from differentiated cells</i>	132
<i>Cloning mice from adult stem cells</i>	133
<i>Creating interspecies stem cells</i>	133
<i>Cloned cells for transplantation medicine</i>	134
<i>Claims of cloning of hESCs</i>	134
Cytogenetics of embryonic stem cells	135
Engraftment, mobilization and expansion of stem cells	136
<i>Adipogenesis induced by adipose tissue-derived stem cells</i>	137
<i>Antisense approach for preservation and expansion of stem cells</i>	137
<i>Biomaterials for ESC growth</i>	138
<i>Chemoattraction of neuronal stem cells through GABA receptor</i>	138
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i>	138
<i>Enhancement of stem cell differentiation by Homspera</i>	139
<i>Ex vivo expansion of human HSCs in culture</i>	139
<i>Ex vivo expansion of MSCs</i>	140
<i>Ex vivo expansion of UCB cells for transplantation</i>	140
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i>	140
<i>Expansion of adult stem cells by activation of Oct4</i>	141
<i>Expansion of transduced HSCs in vivo</i>	141
<i>Expansion of stem cells in vivo by Notch receptor ligands</i>	141
<i>Mobilization of HSCs by growth factors</i>	141
<i>Mobilization of stem cells by cytokines/chemokines</i>	142
<i>Mobilization of adult human HSCs by use of inhibitors</i>	143
<i>Mobilization of stem cells by HYC750</i>	143
<i>Mobilization of stem cells by hyperbaric oxygen</i>	144
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i>	144
<i>Selective mobilization of progenitor cells from bone marrow</i>	144
<i>Selective Amplification</i>	145
<i>Stem cell mobilization by acetylcholine receptor agonists</i>	145
<i>Use of parathyroid hormone to increase HSC mobilization</i>	145
Technologies for inducing differentiation of stem cells	146
<i>Generation of RBCs from hematopoietic stem cells</i>	146
<i>Generation of multiple types of WBCs from hESCs and iPSCs</i>	146
<i>Growth factor-induced differentiation of MAPCs</i>	146
<i>Lineage selection to induce differentiation of hESCs</i>	147
<i>Mechanical strain to induce MSC differentiation</i>	147
<i>Neurotrophin-mediated survival and differentiation of hESCs</i>	147
<i>Synthetic biology and stem cells</i>	148
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i>	148
<i>Use of carbohydrate molecules to induce differentiation of stem cells</i>	149
Limitations of the currently available stem cell lines in the US	149

Stem cell separation	149
Stem cell culture	150
<i>Culture of hMSCs</i>	151
<i>Elimination of contaminating material in stem cell culture</i>	151
<i>Long-term maintenance of MSC multipotency in culture</i>	152
<i>Nanofiber scaffolds for stem cell culture</i>	153
Conversion of stem cells to functioning adipocytes	153
Mass production of ESCs	153
Promoting survival of dissociated hESCs	154
Analysis and characterization of stem cells	154
Harvesting and identification of EPCs	154
Labeling of stem cells	155
Labeling, imaging and tracking of stem cells in vivo	155
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i>	155
<i>Project for imaging in stem cell therapy research</i>	156
<i>Quantum dots for labeling and imaging of stem cells</i>	156
<i>Superparamagnetic iron oxide nanoparticles for tracking MSCs</i>	157
Applications of stem cells	157
Commercial development and applications of adult stem cells	158
<i>Retrodifferentiation of stem cells</i>	158
<i>MultiStem</i>	158
Controlling the maintenance process of hematopoietic stem cells	158
<i>Self renewal and proliferation of HSCs</i>	158
<i>Aging and rejuvenation of HSCs</i>	159
Peripheral blood stem cell transplantation	159
Role of stem cells in regeneration	159
<i>Promotion of regeneration by Wnt/beta-catenin signaling</i>	160
Stem cells and human reproduction	160
<i>Expansion of spermatogonial stem cells</i>	160
<i>Conversion of ESCs into spermatogonial stem cells</i>	160
<i>Conversion of stem cells to oocytes</i>	161
<i>ESCs for treatment of infertility in women</i>	161
<i>Cloning human embryos from oocytes matured in the laboratory</i>	162
<i>In utero stem cell transplantation</i>	162
Innovations in delivery of stem cells	163
<i>Polymeric capsules for stem cell delivery</i>	164
Immunological aspects of hESC transplantation	164
<i>Immunosuppression to prevent rejection of hESC transplants</i>	164
<i>Histocompatibility of hESCs</i>	164
<i>Strategies for promoting immune tolerance of hESCs</i>	165
Stem cells for organ vascularization	165
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i>	166
Advantages and limitations of clinical applications of MSCs	166
Biofusion by genetically engineering stem cells	167
Stem cell gene therapy	167
<i>Combination of gene therapy with nuclear transfer</i>	167
<i>Gene delivery to stem cells by artificial chromosome expression</i>	168
<i>Genetic manipulation of ESCs</i>	168
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i>	169
<i>HSCs for gene therapy</i>	169
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i>	170
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i>	170
<i>Linker based sperm-mediated gene transfer technology</i>	170
<i>Mesenchymal stem cells for gene therapy</i>	170
<i>Microporation for transfection of MSCs</i>	171
<i>Regulation of gene expression for SC-based gene therapy</i>	171
<i>Stem cells and in utero gene therapy</i>	171
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	172
<i>The future of hematopoietic stem cell gene therapy</i>	172
Stem cell pharmaceuticals	172
<i>Cardiomyocytes derived from hESCs</i>	172
<i>ESCs as source of models for drug discovery</i>	173
<i>hESC-derived hepatocytes for drug discovery</i>	174
<i>Pharmaceutical manipulation of stem cells</i>	174
<i>Role of stem cells in therapeutic effects of drugs</i>	176
<i>Stem cells for drug discovery</i>	176
<i>Stem cells for drug delivery</i>	177
<i>Stem cell activation for regeneration by using glucocorticoids</i>	177
<i>Toxicology and drug safety studies using ESCs versus other cells</i>	178
Future challenges for stem cell technologies	180
Study of the molecular mechanism of cell differentiation	180

MBD3-deficient ESC line.....	181
In vivo study of human hemopoietic stem cells.....	181
Stem cell biology and cancer.....	181
Research into plasticity of stem cells from adults.....	182
Stem cells and aging.....	182
Activation of bone marrow stem cells into therapeutic cells.....	183
Role of nitric oxide in stem cell mobilization and differentiation.....	184
Stem cell genes.....	184
<i>Gene expression in hESCs.....</i>	<i>184</i>
<i>The casanova gene in zebrafish.....</i>	<i>185</i>
<i>Nanog gene.....</i>	<i>185</i>
Stem cell proteomics.....	186
<i>hESC phosphoproteome.....</i>	<i>187</i>
<i>Proteomic studies of mesenchymal stem cells.....</i>	<i>187</i>
<i>Proteomic profiling of neural stem cells.....</i>	<i>187</i>
<i>Proteome Biology of Stem Cells Initiative.....</i>	<i>188</i>
Genomic alterations in cultured hESCs.....	188
Hybrid embryos/cybrids for stem cell research.....	188
Generation of patient-specific pluripotent stem cells.....	189
Markers for characterizing hESC lines.....	190
Switch of stem-cell function from activators to repressors.....	190
Stem cell research at academic centers.....	191
International Regulome Consortium.....	192
Companies involved in stem cell technologies.....	192
Concluding remarks about stem cells.....	197
Challenges and future prospects of stem cell research.....	198
4. Clinical Applications of Cell Therapy.....	200
Introduction.....	200
Cell therapy for hematological disorders.....	200
Transplantation of autologous hematopoietic stem cells.....	200
Hemophilias.....	200
<i>Ex vivo cell/gene therapy of hemophilia B.....</i>	<i>200</i>
<i>Cell/gene therapy of hemophilia A.....</i>	<i>201</i>
Hematopoietic stem cell therapy for thrombocytopenia.....	202
Stem cell transplant for sickle cell anemia.....	202
Treatment of chronic acquired anemias.....	203
<i>Implantation of genetically engineered HSCs to deliver rhEpo.....</i>	<i>203</i>
<i>Drugs acting on stem cells for treatment of anemia.....</i>	<i>203</i>
Stem cell therapy of hemoglobinopathies.....	204
Stem cells for treatment of immunoglobulin-light chain amyloidosis.....	204
Future prospects of cell therapy of hematological disorders.....	204
Cell therapy for immunological disorders.....	205
Role of dendritic cells in the immune system.....	205
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures.....	205
Potential of MSCs as therapy for immune-mediated diseases.....	206
Stem cell therapy of chronic granulomatous disease.....	206
Stem cell therapy of X-linked severe combined immunodeficiency.....	207
Stem cell therapy of autoimmune disorders.....	207
<i>Treatment of rheumatoid arthritis with stem cells.....</i>	<i>207</i>
<i>Treatment of Crohn's disease with stem cells.....</i>	<i>208</i>
<i>Stem cell transplants for scleroderma.....</i>	<i>208</i>
Role of T Cells in immunological disorders.....	209
<i>Autologous T cells from adult stem cells.....</i>	<i>209</i>
Cell therapy for graft vs host disease.....	210
<i>MSCs for GVHD.....</i>	<i>211</i>
Cell therapy for viral infections.....	211
<i>T-cell therapy for CMV.....</i>	<i>211</i>
<i>T-cell therapy for HIV infection.....</i>	<i>212</i>
<i>T-cell immunity by Overlapping Peptide-pulsed Autologous Cells.....</i>	<i>212</i>
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells.....</i>	<i>213</i>
<i>Dendritic-cell targeted DNA vaccine for HIV.....</i>	<i>213</i>
Cell therapy of lysosomal storage diseases.....	213
Niemann-Pick disease.....	214
Gaucher's disease.....	214
Fabry's disease.....	215
Cell therapy for diabetes mellitus.....	215
Limitations of current treatment.....	216
<i>Limitations of insulin therapy for diabetes mellitus.....</i>	<i>216</i>
<i>Limitations of pancreatic transplantation.....</i>	<i>216</i>
Islet cell transplantation.....	217

<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i>	217
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i>	217
<i>Drawbacks of islet cell therapy</i>	218
<i>Use of an antioxidant peptide to improve islet cell transplantation</i>	218
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i>	219
<i>A device for delivery of therapeutic cells in diabetes</i>	219
<i>Monitoring of islet cell transplants with MRI</i>	219
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i>	220
Encapsulation of insulin producing cells.....	220
<i>Encapsulated porcine pancreatic islet cells for pancreas</i>	220
<i>Encapsulated insulinoma cells</i>	221
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i>	221
Islet precursor cells	222
Dedifferentiation of β cells to promote regeneration	222
Pharmacological approaches for β cell regeneration	223
Xenotransplantation of embryonic pancreatic tissue	223
Non-pancreatic tissues for generation of insulin-producing cells	224
Exploiting maternal microchimerism to treat diabetes in the child	224
Bio-artificial substitutes for pancreas	224
Role of stem cells in the treatment of diabetes	225
<i>Embryonic stem cells for diabetes</i>	225
<i>HSC transplantation to supplement immunosuppressant therapy</i>	226
<i>Human neural progenitor cells converted into insulin-producing cells</i>	226
<i>Insulin-producing cells derived from UCB stem cells</i>	227
<i>iPS cells for diabetes</i>	227
<i>Isolation of islet progenitor cells</i>	227
<i>Pancreatic progenitor cells Expansion in vitro</i>	228
<i>Pancreatic stem cells</i>	228
<i>Stem cell injection into portal vein of diabetic patients</i>	228
Dendritic cell-based therapy for type 1 diabetes.....	229
Vaccine for diabetes	229
Gene therapy in diabetes	229
<i>Viral vectors for gene therapy of diabetes</i>	230
<i>Genetically engineered dendritic cells</i>	230
<i>Genetically altered liver cells</i>	230
<i>Genetically modified stem cells</i>	231
Companies developing cell therapy for diabetes	231
Concluding remarks about cell and gene therapy of diabetes	232
Cell therapy of gastrointestinal disorders	233
Inflammatory bowel disease	233
Cell therapy for liver disorders.....	234
Types of cells and methods of delivery for hepatic disorders	234
Bioartificial liver	235
<i>Limitations of bioartificial liver</i>	236
Stem cells for hepatic disorders	236
<i>Deriving hepatocytes from commercially available hMSCs</i>	237
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i>	237
<i>MSC derived molecules for reversing hepatic failure</i>	237
Cell-based gene therapy for liver disorders.....	238
<i>Transplantation of genetically modified fibroblasts</i>	238
<i>Transplantation of genetically modified hepatocytes</i>	238
<i>Intraperitoneal hepatocyte transplantation</i>	239
<i>Genetically modified hematopoietic stem cells</i>	239
<i>Use of iPSCs derived from somatic cells for liver regeneration</i>	239
Clinical applications	239
Future prospects of cell-based therapy of hepatic disorders	240
Cell therapy of renal disorders	240
Bioartificial kidney	241
Cell-based repair for vascular access failure in renal disease	241
Mesangial cell therapy for glomerular disease	241
Stem cells for renal disease	242
<i>Role of stem cells in renal repair</i>	242
<i>Bone marrow stem cells for renal disease</i>	242
<i>MSC therapy for renal disease</i>	243
Cell therapy for pulmonary disorders.....	243
Delivery of cell therapy for pulmonary disorders	243
<i>Intratracheal injection of cells for pulmonary hypoplasia</i>	243
Role of stem cells in pulmonary disorders.....	244
<i>Lung stem cells</i>	244
<i>Lung tissue regeneration from stem cells</i>	244
<i>Role of stem cells in construction of the Cyberlung</i>	245

<i>Respiratory epithelial cells derived from UCB stem cells</i>	245
<i>Respiratory epithelial cells derived from hESCs</i>	245
<i>Lung tissue engineering with adipose stromal cells</i>	246
<i>Cell-based tissue-engineering of airway</i>	246
Pulmonary disorders that can be treatable with stem cells.....	246
<i>Acute lung injury and ARDS treated with MSCs</i>	247
<i>Bronchopulmonary dysplasia treated with MSCs</i>	248
<i>Chronic obstructive pulmonary disease treated with MSCs</i>	248
<i>Cystic fibrosis treatment with genetically engineered MSCs</i>	248
<i>Lung regeneration by integrin $\alpha\beta4$-expressing alveolar epithelial cell</i>	249
<i>Pulmonary arterial hypertension treatment with EPCs</i>	249
Cell therapy for disorders of bones and joints.....	250
Repair of fractures and bone defects	250
<i>Adult stem cells for bone grafting</i>	251
<i>Cell therapy for osteonecrosis</i>	251
<i>Cell therapy for cervical vertebral interbody fusion</i>	251
<i>ESCs for bone repair</i>	252
<i>Intrauterine use of MSCs for osteogenesis imperfecta</i>	252
<i>In vivo bone engineering as an alternative to cell transplantation</i>	252
<i>MSCs for repair of bone defects</i>	252
<i>MSCs for repair of bone fractures</i>	255
<i>Osteocele</i>	256
<i>Stem cells for repairing skull defects</i>	256
<i>Stem cell-based bone tissue engineering</i>	256
<i>Spinal fusion using stem cell-based bone grafts</i>	257
Osteoarthritis and other injuries to the joints.....	258
<i>Mosaicplasty</i>	258
<i>Autologous cultured chondrocytes</i>	258
<i>Autologous intervertebral disc chondrocyte transplantation</i>	259
<i>Cartilage repair by genetically modified fibroblasts expressing TGF-β</i>	260
<i>Generation of cartilage from stem cells</i>	261
Role of cell therapy in repair of knee cartilage injuries	262
<i>Role of cells in the repair of anterior cruciate ligament injury</i>	264
Autologous tenocyte implantation in rotator cuff injury repair	264
Platelet injection for tennis elbow	265
Cell therapy of rheumatoid arthritis	265
Cell therapy for diseases of the eye	266
Cell therapy for corneal repair	266
Stem cell therapy for limbal stem cell deficiency	267
Role of stem cells in fibrosis following eye injury	268
Stem cell transplantation for radiation sickness	268
MSCs for treatment of radiation damage to the bone	268
MSCs for regeneration of ovaries following radiotherapy damage	269
Cell therapy for regeneration	269
Stem cells for regenerating organs.....	269
Umbilical cord blood for regeneration	270
Role of stem cells in regeneration of esophageal epithelium	270
Cell therapy for regeneration of muscle wasting	270
Wound healing: skin and soft tissue repair	271
Cells to form skin substitutes for healing ulcers	272
CellSpray for wound repair.....	272
Cell therapy for burns.....	273
Closure of incisions with laser guns and cells	274
Follicular stem cells for skin and wound repair	274
Reprogramming autologous stem cells for wound regeneration	275
Role of amniotic fluid MSCs in repair of fetal wounds	275
Genetically engineered keratinocytes for wound repair.....	275
MSCs for wound healing.....	276
Regeneration of aging skin by adipose-derived stem cells	276
Repair of aging skin by injecting autologous fibroblasts.....	276
Role of cells in tissue engineering and reconstructive surgery	276
Stem cells for tissue repair.....	276
Scaffolds for tissue engineering	277
Improving vascularization of engineered tissues	277
Enhancing vascularization by combining cell and gene therapy	278
Choosing cells for tissue engineering	278
ESCs vs adult SCs for tissue engineering	278
Use of adult MSCs for tissue engineering	279
Nanobiotechnology applied to cells for tissue engineering.....	280
Stem cells for tissue engineering of various organs	280
<i>Engineering of healthy living teeth from stem cells</i>	280

<i>Adipose tissue-derived stem cells for breast reconstruction</i>	281
<i>Improving tissue engineering of bone by MSCs</i>	282
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs</i>	282
Cell-based tissue engineering in genitourinary system	283
<i>Urinary incontinence</i>	283
<i>Tissue engineering of urinary bladder</i>	284
<i>Label retaining urothelial cells for bladder repair</i>	284
<i>MSCs for bladder repair</i>	285
<i>Tissue-engineering of urethra using autologous cells</i>	285
<i>Repair of the pelvic floor with stem cells from the uterus</i>	285
<i>Reconstruction of vagina from stem cells</i>	286
Facial skin regeneration by stem cells as an alternative to face transplant	286
Reconstruction of cartilage for repair of craniofacial defects	286
Cell therapy for rejuvenation	287
Cell therapy for performance enhancement in sports	287
Application of stem cells in veterinary medicine	287
Use of stem cells to repair tendon injuries	287
Stem cells for spinal cord injury in dogs	288

5. Cell Therapy for Cardiovascular Disorders **290**

Introduction to cardiovascular disorders	290
Limitations of current therapies for myocardial ischemic disease	290
Types of cell therapy for cardiovascular disorders	290
Cell-mediated immune modulation for chronic heart disease	291
Human cardiovascular progenitor cells	292
Inducing the proliferation of cardiomyocytes	292
Pericardial origin of colony-forming units	293
Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia	293
Role of splenic myocytes in repair of the injured heart	293
Reprogramming of fibroblasts into functional cardiomyocytes	294
Small molecules to enhance myocardial repair by stem cells	294
Cell therapy for atherosclerotic coronary artery disease	294
MyoCell™ (Bioheart)	295
Cardiac stem cells	295
Cardiomyocytes derived from epicardium	296
Methods of delivery of cells to the heart	297
Cellular cardiomyoplasty	297
IGF-1 delivery by nanofibers to improve cell therapy for MI	297
Non-invasive delivery of cells to the heart by Morph@guide catheter	297
Cell therapy for cardiac revascularization	298
Transplantation of cardiac progenitor cells for revascularization of myocardium	298
Stem cells to prevent restenosis after coronary angioplasty	298
Role of cells in cardiac tissue repair	299
Modulation of cardiac macrophages for repair of infarct	299
Transplantation of myoblasts for myocardial infarction	299
Patching myocardial infarction with fibroblast culture	300
Cardiac repair with myoendothelial cells from skeletal muscle	300
Myocardial tissue engineering	301
Role of stem cells in repair of the heart	302
Role of stem cells in cardiac regeneration following injury	302
Cardiomyocytes derived from adult skin cells	302
Cardiomyocytes derived from ESCs	302
Studies to identify subsets of progenitor cells suitable for cardiac repair	303
Technologies for preparation of stem cells for cardiovascular therapy	304
<i>Pravastatin for expansion of endogenous progenitor and stem cells</i>	304
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i>	304
<i>Expansion of adult cardiac stem cells for transplantation</i>	305
<i>Role of MSCs in growth of CSCs</i>	305
Role of ESCs in repair of the heart	305
<i>ESC transplantation for tumor-free repair of the heart</i>	306
Transplantation of stem cells for myocardial infarction	307
<i>Autologous bone marrow-derived stem cell therapeutics</i>	307
<i>Autologous bone marrow-derived mesenchymal precursor stem cells</i>	307
<i>Transplantation of cord blood stem cells</i>	307
<i>Transplantation of hESCs</i>	308
<i>Transplantation of HSCs</i>	308
<i>Transplantation of autologous angiogenic cell precursors</i>	309
<i>Transplantation of adipose-derived stem cells</i>	309
<i>Transplantation of bone marrow-derived cells for myocardial infarct</i>	310
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	311
<i>Transplantation of endothelial cells</i>	311

<i>Transplantation of cardiomyocytes differentiated from hESCs</i>	312
Stem cell therapy for cardiac regeneration	312
<i>Regeneration of the chronic myocardial infarcts by HSC therapy</i>	312
<i>Human mesenchymal stem cells for cardiac regeneration</i>	313
<i>In vivo tracking of MSCs transplanted in the heart</i>	314
<i>MSCs for hibernating myocardium</i>	314
<i>Simultaneous transplantation of MSCs and skeletal myoblasts</i>	315
Transplantation of genetically modified cells	315
Transplantation of genetically modified MSCs	315
Transplantation of cells secreting vascular endothelial growth factor	315
Transplantation of genetically modified bone marrow stem cells	315
Cell transplantation for congestive heart failure	315
AngioCell gene therapy for congestive heart failure	316
Injection of adult stem cells for CHF	317
Intracoronary infusion of cardiac stem cells	317
Myoblasts for treatment of congestive heart failure	318
Stem cell therapy for dilated cardiac myopathy	318
Role of cell therapy in cardiac arrhythmias	318
Atrioventricular conduction block	319
<i>Genetically engineered cells as biological pacemakers</i>	319
Ventricular tachycardia	320
Prevention of myoblast-induced arrhythmias by genetic engineering	320
ESCs for correction of congenital heart defects	321
Cardiac progenitors cells for treatment of heart disease	321
Autologous stem cells for chronic myocardial ischemia	322
Role of cells in cardiovascular tissue engineering	322
Construction of blood vessels with cells	322
<i>Engineered arteries for bypass grafts</i>	323
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts	323
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	323
UCB progenitor cells for engineering heart valves	323
Cell therapy for peripheral vascular disease	324
ALD-301	324
Cell/gene therapy for PVD	324
Cell therapy for CLI in diabetics	324
Colony stimulating factors for enhancing peripheral blood stem cells	325
Intramuscular autologous bone marrow cells	325
Ixmyelocel-T cell therapy for critical limb ischemia	325
Clinical trials of cell therapy in cardiovascular disease	326
Mechanism of the benefit of cell therapy for heart disease	328
A critical evaluation of cell therapy for heart disease	329
Publications of clinical trials of cell therapy for CVD	329
Current status of cell therapy for cardiovascular disease	330
Future directions for cell therapy of CVD	330
Prospects of adult stem cell therapy for repair of heart	331
Combination of cells with biomedical scaffolds	331
Regeneration of cardiomyocytes without use of cardiac stem cells	331
6. Cell Therapy for Cancer	334
Introduction	334
Cell therapy technologies for cancer	334
Cell-based delivery of anticancer therapy	335
Cellular immunotherapy for cancer	335
Treatments for cancer by ex vivo mobilization of immune cells	336
Granulocytes as anticancer agents	336
Neutrophil granulocytes in antibody-based immunotherapy of cancer	337
Cancer vaccines	337
Autologous tumor cell vaccines	337
<i>BIOVAXID</i>	338
<i>OncoVAX</i>	338
<i>Tumor cells treated with dinitrophenyl</i>	338
Vaccines that simultaneously target different cancer antigens	338
Gene modified cancer cells vaccines	339
<i>GVAX cancer vaccines</i>	339
<i>K562/GM-CSF</i>	339
Active immunotherapy based on antigen specific to the tumor	340
The use of dendritic cells for cancer vaccination	340
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA</i>	340
<i>Dendritic cell-targeted protein vaccines</i>	341
<i>Dendritic/tumor cell fusion</i>	341
<i>Genetically modified dendritic cells</i>	341

<i>In vivo</i> manipulation of dendritic cells	342
Preclinical and clinical studies with DC vaccines	342
Vaccines based on dendritic cell-derived exosomes	343
Limitations of DC vaccines for cancer	343
Future developments to enhance clinical efficacy of DC vaccines	343
Lymphocyte-based cancer therapies	345
Adoptive cell therapy	345
Chimeric antigen receptor T cells	346
Combination of antiangiogenic agents with ACT	347
Expansion of antigen-specific cytotoxic T lymphocytes	347
Rescue of CD8+ T cells for use in tumor immunotherapy	348
Tumor infiltrating lymphocytes	348
Genetic engineering of tumor cells to activate T helper cells	348
Hybrid cell vaccination	349
Chemoimmunotherapy	349
Stem cell-based anticancer therapies	350
Stem cell transplantation in cancer	350
Peripheral blood stem cell transplantation	350
Stem cell transplantation for hematological malignancies	352
Long-term results of HSC transplantation	353
Prediction of T-cell reconstitution after HSC transplantation	353
HSC transplantation followed by GM-CSF-secreting cell vaccines	354
HSC transplantation for renal cell cancer	354
Complications of stem cell transplants in cancer	354
Graft-versus-host disease (GVHD)	354
Delayed immune reconstitution leading to viral infections and relapse	355
Tumor cell contamination	355
Neurological complications	355
Hepatic veno-occlusive disease	356
Current status of the safety of allogeneic HSC transplantation	356
Complications of PBSC transplantation in children	356
Role of MSCs in cancer	357
MSC-mediated delivery of anticancer therapeutics	357
Nonmyeloablative allogeneic hematopoietic stem cell transplantation	358
Umbilical cord blood transplant for leukemia	358
hESC-derived NK cells for treatment of cancer	359
ESC vaccine for prevention of lung cancer	359
Genetic modification of stem cells for cancer therapy	360
Genetic modification of hematopoietic stem cells	360
Use of hematopoietic stem cells to deliver suicide genes to tumors	360
Delivery of anticancer agents by genetically engineered MSCs	360
Mesenchymal progenitor cells for delivery of oncolytic adenoviruses	361
Genetically modified NSCs for treatment of neuroblastoma	361
Innovations in cell-based therapy of cancer	362
Use of immortalized cells	362
Cancer therapy based on natural killer cells	362
Mesothelin as a target for cancer immunotherapy	363
Nanomagnets for targeted cell-based cancer gene therapy	363
Implantation of genetically modified encapsulated cells for anticancer therapy	363
Antiangiogenesis therapy by implantation of microencapsulated cells	363
Recombinant tumor cells secreting fusion protein	364
NovaCaps®, for pancreatic cancer	364
A device for filtering cancer and stem cells in the blood	364
Cancer stem cells	365
Role of integrative nuclear signaling in stem cell development	365
Cancer stem cell markers	365
Breast cancer stem cells	366
Role of intestinal stem cells in intestinal polyposis	366
Role of endothelial progenitor cells in tumor angiogenesis	367
Role of cancer stem cells in metastases	367
Therapeutic implications of cancer stem cells	367
Targeting cancer stem cells in leukemia	368
Targeting stem cells in ovarian cancer	368
Targeting cancer stem cells to screen anticancer drugs	369
Cell-based therapies for malignant brain tumors	369
Bone morphogenetic protein for inhibition of glioblastoma multiforme	369
Dendritic cell therapy for brain tumors	370
Encapsulated cells for brain tumors	370
Immunotherapy of GBM targeting cancer stem cells	371
Mesenchymal stem cells for the treatment of gliomas	371
Neural stem cells for drug/gene delivery to brain tumors	372

<i>Role of cancer stem cells in resistance to radiotherapy</i>	373
<i>Targeting stem cells in brain tumors</i>	373
Companies involved in cell-based cancer therapy	374
American Association for Cancer Research and ESCs	375
Future of cell-based immunotherapy for cancer	376

7. Cell Therapy for Neurological Disorders..... 378

Introduction	378
Regeneration of the nervous system by endogenous stem cells	378
Molecular mechanism of neurogenesis.....	378
Generation of neurons from astroglia.....	379
In vivo cell replacement therapy by locally induced neural progenitor cells.....	379
Types of cells used for treatment of neurological disorders	380
Activated T lymphocytes.....	380
Differentiation of placenta-derived multipotent cells into neurons.....	380
Mesenchymal stem cells induced to secrete neurotrophic factors.....	381
Neural stem cells.....	381
<i>Development of human CNS stem cells</i>	381
<i>Distinction between NSCs and intermediate neural progenitors</i>	382
<i>Embryonic stem cell-derived neurogenesis</i>	382
<i>Induction of NSCs from hESCs</i>	383
<i>Mechanism of migration of neural stem cells to sites of CNS injury</i>	384
<i>Monitoring of implanted NSCs labeled with nanoparticles</i>	384
<i>Neural progenitor cells</i>	385
<i>Neural stem cells as therapeutic delivery vehicles</i>	386
<i>Neural stem cells in the subventricular zone of the brain</i>	387
<i>Oligodendrocyte progenitor cells</i>	387
<i>Promotion of neural stem cells expansion by betacellulin</i>	387
<i>Proteomics of neural stem cells</i>	387
<i>Regulation of neural stem cells in the brain</i>	388
<i>Role of CSF proteins in regulation of neural progenitor cells</i>	389
<i>Sequencing the transcriptomes of neural stem cells</i>	389
<i>Study of neural differentiation of hESCs by NeuroStem Chip</i>	389
<i>Transformation of neural stem cells into other cell types</i>	390
<i>Use of epidermal neural crest stem cells for neurological disorders</i>	390
Olfactory epithelium stem cells for transplantation in the CNS.....	390
Development of CNS cells from non-CNS stem cells.....	390
<i>Derivation of CNS cells from peripheral nervous system</i>	391
<i>Hair-follicle stem cells for neural repair</i>	392
<i>Stem cells from human umbilical cord blood for CNS disorders</i>	392
Immortalized cells for CNS disorders.....	392
Fetal tissue transplants.....	393
Choroid plexus cells.....	394
Laboratory mice with human brain cells.....	394
Expansion of adult human neural progenitors.....	394
Neurospheres.....	395
Dental pulp cells for neuroprotection.....	395
Ideal cells for transplantation into the nervous system.....	395
Cell therapy techniques for neurological applications	396
Carbon nanotubes to aid stem cell therapy of neurological disorders.....	396
Cells used for gene therapy of neurological disorders.....	396
<i>Fibroblasts</i>	396
<i>Stem cells</i>	397
<i>Neuronal cells</i>	397
<i>Immortalized neural progenitor cells</i>	397
<i>Astrocytes</i>	398
<i>Cerebral endothelial cells</i>	398
<i>Human retinal pigmented epithelial cells</i>	399
Enhancement of growth of stem cells in the brain by drugs.....	399
<i>C3-induced differentiation and migration of NPC for repair of the brain</i>	400
Stem cell therapies of neurological disorders combined with HBO.....	400
hESCs for CNS repair.....	400
Methods of delivery of cells to the CNS.....	401
<i>Engineered stem cells for drug delivery to the brain</i>	401
Neuronal differentiation of stem cells.....	402
Stem cells preparations for CNS disorders.....	402
Tracking of stem cells in the CNS by nanoparticles and MRI.....	403
Use of neural stem cells to construct the blood brain barrier.....	404
<i>Encapsulated cells</i>	404
<i>CNS neotissue implant</i>	404
<i>Intrathecal delivery of stem cells</i>	405

<i>CNS delivery of cells by catheters</i>	406
<i>Intravascular administration</i>	406
Neurological disorders amenable to cell therapy	406
Neuroprotection by cell therapy	407
<i>Cells secreting neuroprotective substances</i>	407
<i>Stem cells for neuroprotection</i>	407
<i>Neuroprotection by intravenous administration of HSCs</i>	407
<i>Human UCB-derived stem cells for the aging brain</i>	408
<i>hESC transplantation to prevent cognitive impairment from radiation</i>	408
Neurodegenerative disorders	408
<i>Role of stem cells in neurodegenerative disorders</i>	408
<i>MSCs for therapy of neurodegenerative disorders</i>	409
<i>Role of NSCs in disorders associated with aging brain</i>	410
<i>NSCs for improving memory</i>	411
Parkinson's disease	411
<i>Origin and fate of dopamine neurons</i>	412
<i>Human dopaminergic neurons for PD</i>	413
<i>Graft survival-enhancing drugs</i>	413
<i>Xenografting porcine fetal neurons</i>	414
<i>Encapsulated cells for PD</i>	414
<i>Stem cells for PD</i>	414
<i>Stem cells for production of glial derived neurotrophic factor</i>	417
<i>Potential of regeneration of endogenous stem cells in PD</i>	417
<i>Human retinal pigment epithelium cells for PD</i>	417
<i>Coaxing hESCs to produce dopamine</i>	418
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i>	418
<i>Transplantation of embryonic medial ganglionic eminence cells</i>	418
<i>Delivery of cells for PD</i>	419
<i>MSCs for multiple system atrophy</i>	419
Cell therapy for Huntington's disease.....	420
<i>Fetal striatal cell transplantation</i>	420
<i>Transplantation of encapsulated porcine choroids plexus cells</i>	420
Cell therapy for Alzheimer's disease	421
<i>Neural stem cell implantation for Alzheimer's disease</i>	421
<i>Implantation of genetically engineered cells producing NGF</i>	421
Cell therapy for amyotrophic lateral sclerosis	422
<i>Stem cell techniques for study of ALS</i>	422
<i>Use of stem cells for ALS</i>	423
<i>Transplantation of glial restricted precursors in ALS</i>	424
<i>Stem cell-based drug discovery for ALS</i>	425
Cell therapy for demyelinating disorders	425
<i>Autologous bone marrow stem cell therapy for MS</i>	426
<i>ESCs for remyelination</i>	426
<i>Fusokine method of personalized cell therapy of MS</i>	426
<i>Hematopoietic stem cell transplantation for MS</i>	427
<i>Mechanism of repair of demyelination after NSC transplantation</i>	427
<i>Neural progenitor cells for neuroprotection in MS</i>	428
<i>T cell-based personalized vaccine for MS</i>	428
<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i>	429
<i>X-linked adrenoleukodystrophy</i>	429
Cell therapy of stroke	429
<i>Adult stem cell therapy in stroke</i>	430
<i>Implantation of genetically programmed ESCs</i>	430
<i>Intravenous infusion of MSCs</i>	431
<i>Intravenous infusion of human UCB stem cells</i>	431
<i>Intracerebral administration of human adipose tissue stromal cells</i>	432
<i>Neural stem cell therapy for stroke</i>	432
<i>Transplantation of encapsulated porcine choroids plexus</i>	433
<i>Transplantation of fetal porcine cells</i>	434
<i>Role of cell therapy in management of stroke according to stage</i>	434
<i>Clinical trials of cell therapy for stroke</i>	434
<i>Future of cell therapy for stroke</i>	436
Cell therapy of traumatic brain injury	437
<i>Cell/gene therapy for TBI</i>	437
<i>Clinical trials of autologous HSC therapy for TBI</i>	437
<i>Limitations of stem cell therapy for acute TBI</i>	438
<i>Improving the microenvironments of transplanted cells in TBI</i>	438
Cell therapy for spinal cord injury	439
<i>Autoimmune T cells against CNS myelin-associated peptide</i>	439
<i>Fetal neural grafts for SCI</i>	439
<i>Olfactory-ensheathing cells for SCI</i>	439

<i>Oligodendrocyte precursor cells for treatment of SCI</i>	440
<i>Schwann cell transplants for SCI</i>	440
<i>Transplantation of glial cells for SCI</i>	440
Stem cells for SCI	441
<i>Bone marrow stem cells for SCI</i>	441
<i>Embryonic stem cells for SCI</i>	441
<i>Transplantation of induced pluripotent stem cells in SCI</i>	442
<i>Transplantation of MSCs for SCI</i>	442
<i>Transplantation of NSCs for SCI</i>	443
<i>Transplantation of human dental pulp stem cells</i>	443
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i>	444
Spinal stem cells for treatment of ischemic injury of spinal cord	444
Combined approaches for regeneration in SCI	444
<i>Combined cell/gene therapy for SCI</i>	445
Delivery of cells in SCI	445
<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i>	445
<i>Intravenous injection of stem cells for spinal cord repair</i>	446
Clinical applications of stem cells for SCI	446
<i>Autologous bone marrow cell transplantation for SCI</i>	446
<i>Cell therapy of syringomyelia</i>	446
Cell therapy for neurogenetic disorders	447
<i>Hurler's syndrome treated with stem cells</i>	447
<i>Krabbe's disease treated with UCB stem cells</i>	447
<i>Krabbe's disease treated with combination of cell and gene therapy</i>	448
<i>Mitochondrial encephalomyopathies treated with stem cells</i>	448
<i>Sanfilippo syndrome type B treated with UCB stem cells</i>	449
Cell therapy for lysosomal storage disorders	449
<i>Cell therapy for Batten disease</i>	449
<i>Cell/gene therapy for Farber's disease</i>	450
<i>Genetically modified HSCs for metachromatic leukodystrophy</i>	450
<i>Neural stem cells for lysosomal storage disorders</i>	451
Cell therapy of epilepsy	451
<i>Cell therapy of posttraumatic epilepsy</i>	451
<i>Cell therapy for temporal lobe epilepsy</i>	452
<i>Cell therapy for pharmaco-resistant epilepsies</i>	452
Cell therapy for developmental neurological disorders	452
Cell therapy for cerebral palsy	453
Cell therapy for muscle disorders	453
<i>Duchenne muscular dystrophy</i>	453
<i>Combination of cell and pharmacotherapy for DMD</i>	454
<i>Myoblast transplant for DMD</i>	454
<i>Myoblast-based gene transfer</i>	455
<i>Myoblasts lacking the MyoD gene</i>	455
<i>Myoblast injection for treatment of other muscular dystrophies</i>	455
<i>Role of satellite cells in the treatment of DMD</i>	456
<i>Stem cells for DMD</i>	456
Cell therapy for Autism	458
Management of chronic intractable pain by cell therapy	458
<i>Implantation of chromaffin cells</i>	459
<i>Role of stem cells in management of pain</i>	459
<i>Implantation of astrocytes secreting enkephalin</i>	459
<i>Cells for delivery of antinociceptive molecules</i>	460
<i>Implantation of genetically engineered cells</i>	460
<i>Cell therapy for low back pain</i>	460
Cell therapy for neuroendocrine disorders	461
<i>Pituitary stem cells</i>	461
Cell therapy for retinal degenerative disorders	461
<i>Human retinal stem cells</i>	462
<i>Delivery of CNTF by encapsulated cell intraocular implants</i>	463
<i>Stem cell transplantation in the retina</i>	463
<i>ESCs for retinal degenerative disorders</i>	464
<i>hESC-derived RPE cells for macular dystrophy</i>	464
<i>Neuroprotective effect of neural progenitor cell transplantation</i>	464
<i>Genetically engineered retinal pigmented epithelial cell lines</i>	465
<i>Combining cell and gene therapies for retinal disorders</i>	465
Stem cell therapy for hearing loss	465
Cell therapy for peripheral nerve lesions	466
<i>Cell transplants for peripheral nerve injuries</i>	466
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i>	466
Complications of cell therapy of CNS disorders	466
<i>Tumor formation after CNS transplantation of stem cells</i>	466

<i>Uncontrolled differentiation of implanted cells</i>	466
<i>Donor stem cell-derived brain tumor</i>	467
Clinical trials of cell therapy in neurological disorders	467
Future prospects for cell therapy of CNS disorders	468

8. Ethical and Political Aspects of Cell therapy..... 470

Introduction	470
Political and ethical aspects of hESC research in the US	470
Ethical issues concerning fetal tissues	470
<i>Morality and hESC research</i>	470
Opponents of hESC research in the US	471
<i>Use of hESCs in NIH-supported research</i>	472
<i>Politics of hESC research in the US</i>	473
<i>Public opinion in the US about hESC research</i>	475
<i>Human stem cell cloning in the US</i>	476
<i>Stem cell guidelines of various US institutions</i>	477
Ethics of transplanting human NSCs into the brains of nonhuman primates	477
Stem cell lines available worldwide	478
Stem cell policies around the world	479
Countries with no defined policies on hESC research.....	479
Australia	480
Canada.....	480
China	481
Denmark.....	482
France	482
Germany.....	482
India	484
Ireland	485
Israel	485
Italy	485
Japan	486
The Netherlands	486
Saudi Arabia.....	487
Singapore	487
South Africa	487
South Korea	488
Spain	488
Sweden	488
Switzerland	489
United Kingdom	489
<i>ESC bank</i>	490
European Union	491
<i>EU guidelines for stem cell research</i>	491
<i>EMBO's recommendations for stem cell research</i>	492
Public opinion in Europe about hESC research.....	493
United Nations, cloning and nuclear transfer.....	494
The Embryo Project for information on ESC research	495
Concluding remarks about ethics of ESC research	495
Ethical issues concerning umbilical cord blood	495
Cell therapy tourism	496

9. Safety and Regulatory Aspects of Cell Therapy 498

Introduction	498
Safety issues of cell therapy	498
Immune-mediated reactions to transplanted stem cells	498
Human virus infections associated with stem cell transplantation	499
<i>Herpes simplex virus type 1</i>	499
<i>Cytomegalovirus</i>	499
Opportunistic infections among hematopoietic stem cell transplant recipients	499
Cord colitis syndrome	499
Carcinogenic potential of stem cells and its prevention	500
FDA safety regulations for cell and tissue products	500
FDA Guidance on license applications for umbilical cord blood products.....	501
Regulation of cord blood banks in the US	501
Regulatory issues for biotechnology-derived drugs	501
Regulation of cell selection devices for PBSCs at point of care	502
FDA rules for human cells and tissues	503
FDA regulation of fetal cellular or tissue products	503
FDA and clinical trials using hESCs	504
Cell and gene therapy INDs placed on hold by the FDA	504
Regulatory issues for genetically engineered cell transplants	505

FDA guidelines for human tissue transplantation	505
Xenotransplantation	505
Clinical Protocol Review and Oversight	506
Informed consent and patient education	506
Xenotransplantation product sources	506
FDA guidelines for xenografts	507
Regulations relevant to cell therapy in the European Union	508
Regulations about use of stem cells in the EU	509
EMA regulation of cell/gene therapy	509
Guidelines for cell therapy in the UK	510
NIH and stem cells	511
hESC lines approved under the new NIH guidelines	511
Clinical trials in cell therapy	512
Stem cell patents	512
Stem cell patents in the United States	512
<i>Current status of Thomson patents at WARF</i>	513
Stem cell patents in the European Union	513

Tables

Table 1-1: Landmarks in the history of cell therapy	28
Table 1-2: Examples of cells involved in various diseases	33
Table 2-1: Types of human cells used in cell therapy	36
Table 2-2: A selection of companies providing cell culture media	40
Table 2-3: A sampling of companies supplying cell sorters	45
Table 2-4: Companies involved in cell-based drug discovery	52
Table 2-5: Methods of delivery of cells for therapeutic purposes	54
Table 2-6: Therapeutic applications of encapsulated cells	58
Table 2-7: Companies working on encapsulated cell technology	60
Table 2-8: Molecular imaging methods for tracking cells in vivo	65
Table 3-1: Companies involved in cord blood banking as a source of stem cells	102
Table 3-2: Sources of adult human stem cells	112
Table 3-3: Comparison of human stem cells according to derivation	122
Table 3-4: Enhancing engraftment, mobilization and expansion of stem cells	136
Table 3-5: Applications of stem cells	157
Table 3-6: Advantages and limitations of methods for optimizing MSCs	167
Table 3-7: Growth factors with positive effects on stem cells and applications	175
Table 3-8: Examples of drugs that induce granulocytopenia at stem cell level	179
Table 3-9: Academic institutes involved in stem cell research	191
Table 3-10: Companies involved in stem cell technologies	192
Table 4-1: Therapeutic applications of regulatory T cells (T-regs)	209
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes	215
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes	231
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation	247
Table 4-5: Cell-based repair of knee cartilage damage	263
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders	290
Table 5-2: Clinical trials of cell therapy in cardiovascular disease	326
Table 6-1: Cell therapy technologies used for cancer	334
Table 6-2: Companies involved in developing cell-based therapies for cancer	374
Table 7-1: Experimental use of immortalized cells for CNS disorders	392
Table 7-2: Combination of stem cells and HBO in models of neurological disorders	400
Table 7-3: Methods for delivering cell therapies in CNS disorders	401
Table 7-4: Neurological disorders amenable to cell therapy	406
Table 7-5: Types of cell used for investigative treatment of Parkinson's disease	411
Table 7-6: Status of cell therapies for Parkinson's disease	412
Table 7-7: Role of cell therapy in management of stroke according to stage	434
Table 7-8: Clinical trials of cell therapy for stroke: completed, ongoing and pending	434
Table 7-9: Clinical trials with cell-based therapies in neurological disorders (excluding stroke)	467
Table 8-1: Listed numbers of stem cell lines around the world as of end of 2008	478
Table 8-2: Stem cell policies around the world	479
Table 8-3: European public attitudes about research involving human stem cells	494
Table 9-1: Possible adverse reactions and safety issues of cell therapy	498

Figures

Figure 1-1: Interrelationships of cell therapy to other technologies	30
Figure 1-2: Interrelationships of gene, cell and protein therapies	32
Figure 3-1: A simplified biological scheme of embryonic stem Cells	73
Figure 3-2: Steps of iPS cell production	106

Figure 3-3: Flow chart of development of stem cells with potential bottlenecks.....	198
Figure 5-1: hESC-derived cardiomyocytes from laboratory to bedside	303
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells	344
Figure 6-2: Stem cell transplantation techniques	350
Figure 7-1: Stem cells that can give rise to neurons	386
Figure 7-2: Approaches to stem cell therapy in stroke	430